Bristol pulls ahead of Amgen
The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
Revolution mortgages royalties for more cash
“We need all the capital we can get our hands on," the company states.
ArriVent goes Further into PACC mutations
The group is aiming for accelerated approval with the upcoming Alpacca trial.
Exelixis claims a next-generation colorectal win
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
Kura joins the pivotal menin push
The menin inhibitor battle shapes up with Kura, Syndax and J&J all now in phase 3.
